Latest news with #ELV
Yahoo
a day ago
- Business
- Yahoo
High Growth Tech Stocks in Asia Featuring Three Prominent Companies
As global markets navigate the complexities of trade policies, with smaller-cap indexes showing positive returns despite lagging behind major counterparts, Asia's tech sector continues to capture attention amid evolving economic landscapes. In this context, identifying high-growth tech stocks requires a keen understanding of market dynamics and potential resilience to external pressures, making it essential to focus on companies that demonstrate robust innovation and adaptability. Name Revenue Growth Earnings Growth Growth Rating Suzhou TFC Optical Communication 29.68% 30.37% ★★★★★★ Fositek 26.71% 33.90% ★★★★★★ Shengyi Electronics 22.99% 35.16% ★★★★★★ Shanghai Huace Navigation Technology 24.40% 23.42% ★★★★★★ Range Intelligent Computing Technology Group 27.31% 28.63% ★★★★★★ ALTEOGEN 54.36% 69.84% ★★★★★★ Nanya New Material TechnologyLtd 22.72% 63.29% ★★★★★★ PharmaResearch 24.38% 25.85% ★★★★★★ eWeLLLtd 24.95% 24.40% ★★★★★★ JNTC 54.24% 87.93% ★★★★★★ Click here to see the full list of 493 stocks from our Asian High Growth Tech and AI Stocks screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★☆☆ Overview: SUNeVision Holdings Ltd. is an investment holding company that offers data centre and IT facility services in Hong Kong, with a market capitalization of approximately HK$27.77 billion. Operations: SUNeVision Holdings generates revenue primarily from its data centre and IT facilities services, totaling HK$2.64 billion, along with additional income from Extra-Low Voltage (ELV) and IT systems amounting to HK$217.70 million. SUNeVision Holdings, with a robust 19.1% annual revenue growth, outpaces the Hong Kong market average of 8.1%. The company's earnings have also seen a commendable increase, growing by 18.3% annually, which is significantly higher than the local market's 10.3%. Notably, their R&D investment strategy reflects a commitment to innovation; however, specific expenditure figures are crucial for evaluating its impact on future capabilities and market position. Despite challenges in covering debt through operating cash flow, SUNeVision maintains a promising trajectory in the tech sector with an anticipated high return on equity at 23.2% in three years' time. Click here to discover the nuances of SUNeVision Holdings with our detailed analytical health report. Explore historical data to track SUNeVision Holdings' performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Kingboard Laminates Holdings Limited is an investment holding company that manufactures and sells laminates across the People's Republic of China, Europe, other Asian countries, and the United States, with a market cap of HK$28.17 billion. Operations: The company primarily generates revenue from its laminates segment, contributing HK$18.30 billion, with additional income from properties and investments at HK$126.67 million and HK$109.81 million, respectively. Kingboard Laminates Holdings has demonstrated a robust financial performance with earnings soaring by 46.1% over the past year, significantly outpacing the electronics industry's average growth of 17.1%. This surge is supported by an aggressive R&D investment strategy, crucial for maintaining its competitive edge in a rapidly evolving tech landscape. The company also announced a special dividend of HKD 0.3 per share, reflecting confidence in its financial health and commitment to shareholder returns. With annual earnings expected to grow by 23.2%, Kingboard is strategically positioned to leverage market opportunities, particularly as it continues expanding its product offerings in high-demand sectors. Take a closer look at Kingboard Laminates Holdings' potential here in our health report. Gain insights into Kingboard Laminates Holdings' historical performance by reviewing our past performance report. Simply Wall St Growth Rating: ★★★★★☆ Overview: Dmall Inc. is an investment holding company that offers retail digitalization solutions to retailers across various regions including China, Hong Kong, Macau, the Philippines, Malaysia, Singapore, and Poland with a market capitalization of approximately HK$9.26 billion. Operations: Dmall Inc. generates revenue primarily from its Retail Core Service Cloud, contributing CN¥1.81 billion, while its E-Commerce Service Cloud adds CN¥4.28 million to the total revenue stream. Dmall, despite a challenging fiscal year with a net loss widening to CNY 2.20 billion from CNY 592.36 million, shows promising signs of recovery with revenue up by 17.3% to CNY 1.86 billion. This growth is underpinned by significant R&D investments aimed at innovation and market expansion in the competitive tech landscape of Asia. Looking ahead, Dmall is expected to turn profitable within three years, bolstered by an anticipated annual earnings growth rate of 108.17%, reflecting its potential resilience and adaptability in the high-growth tech sector. Delve into the full analysis health report here for a deeper understanding of Dmall. Learn about Dmall's historical performance. Unlock our comprehensive list of 493 Asian High Growth Tech and AI Stocks by clicking here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1686 SEHK:1888 and SEHK:2586. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
Insiders At Elevance Health Sold US$6.9m In Stock, Alluding To Potential Weakness
Over the past year, many Elevance Health, Inc. (NYSE:ELV) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag. While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Over the last year, we can see that the biggest insider sale was by the Executive VP & President of Commercial Health Benefits, Charles Kendrick, for US$3.2m worth of shares, at about US$432 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$384). So it may not tell us anything about how insiders feel about the current share price. In the last year Elevance Health insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! View our latest analysis for Elevance Health If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations. The last quarter saw substantial insider selling of Elevance Health shares. Specifically, insiders ditched US$3.5m worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap. Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Elevance Health insiders own 0.1% of the company, currently worth about US$101m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders. Insiders haven't bought Elevance Health stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. It is good to see high insider ownership, but the insider selling leaves us cautious. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Elevance Health. You'd be interested to know, that we found 1 warning sign for Elevance Health and we suggest you have a look. But note: Elevance Health may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
5 days ago
- Business
- Yahoo
Insiders At Elevance Health Sold US$6.9m In Stock, Alluding To Potential Weakness
Over the past year, many Elevance Health, Inc. (NYSE:ELV) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag. While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Over the last year, we can see that the biggest insider sale was by the Executive VP & President of Commercial Health Benefits, Charles Kendrick, for US$3.2m worth of shares, at about US$432 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$384). So it may not tell us anything about how insiders feel about the current share price. In the last year Elevance Health insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below! View our latest analysis for Elevance Health If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations. The last quarter saw substantial insider selling of Elevance Health shares. Specifically, insiders ditched US$3.5m worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap. Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Elevance Health insiders own 0.1% of the company, currently worth about US$101m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders. Insiders haven't bought Elevance Health stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. It is good to see high insider ownership, but the insider selling leaves us cautious. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Elevance Health. You'd be interested to know, that we found 1 warning sign for Elevance Health and we suggest you have a look. But note: Elevance Health may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Elevance Looks Cheap Now: But is it Time to Buy or Dodge?
Elevance Health, Inc. ELV, a leading U.S. health benefits provider, appears to be trading at a discount. Its forward 12-month P/E ratio stands at just 10.35X, significantly below its five-year median of 13.46X and the industry average of 13.86X. Compared to peers, UnitedHealth Group Incorporated UNH and Humana Inc. HUM, which trade at 12.06X and 14.73X, respectively, ELV looks attractively valued. It currently holds a Zacks Value Score of A, highlighting strong valuation fundamentals. But is this discount a sign of hidden opportunity, or a red flag? Let's explore the drivers behind Elevance's valuation and its long-term outlook. Image Source: Zacks Investment Research Headquartered in Indianapolis, Elevance is well-positioned for sustained growth, underpinned by strategic initiatives across its commercial and government segments. Elevance continues to see steady growth in its commercial segment. In 2024, risk-based and fee-based commercial memberships grew 4.6% and 1% year-over-year. Its Individual Commercial business is especially strong, reporting a 14.2% surge in the first quarter of 2025 alone. By exiting underperforming markets, Elevance has streamlined its government business, improving overall efficiency. It also has room to expand its Medicare Advantage footprint in underpenetrated states, which could unlock future and dental memberships continue to witness growing momentum. With a Return on Invested Capital of 9.94%, far above the industry average of 5.79%, Elevance demonstrates superior capital deployment. Its $84.1 billion market cap gives it the scale to pursue strategic acquisitions and reallocations toward higher-margin businesses. ELV remains committed to returning capital to shareholders. In the first quarter of 2025 alone, it repurchased $880 million worth of shares and had $8.4 billion remaining under its buyback authorization. Its dividend yield of 1.82% also exceeds the industry average of 1.40%. Despite headwinds in the broader market, ELV shares have gained 1.9% year to date, outperforming both the industry and the S&P 500. In contrast, UnitedHealth and Humana have posted declines, reflecting broader sectoral pressure. Image Source: Zacks Investment Research The Zacks Consensus Estimate for Elevance's 2025 and 2026 EPS implies a 4.2% and 13.8% uptick, respectively, on a year-over-year basis. The estimates remained stable over the past week. Moreover, the consensus mark for 2025 and 2026 revenues suggests an 11.2% and 7.1% increase, respectively. The company beat earnings estimates in three of the past four quarters and missed once. This is depicted in the figure below. Elevance Health, Inc. price-eps-surprise | Elevance Health, Inc. Quote Despite its strengths, Elevance faces some notable challenges. A key concern is the decline in Medicaid and Medicare Supplement membership, leading to both overall membership losses and reduced revenues. A drop in government funding could put additional pressure on profitability. Increasing medical costs pose a massive challenge as industry players continue to struggle with rising utilization and squeezing margins. The company's benefit expense ratio, measuring the portion of premiums spent on claims, has been increasing, rising from 87% in 2023 to 88.5% in 2024. Our estimate suggests it could reach 88.7% in 2025, signaling further pressure on earnings. Policy shifts such as the Most Favored Nation drug pricing model introduced by the Trump administration have rattled the Pharmacy Benefit Management (PBM) industry. With major PBM exposure, Elevance — like UnitedHealth, CVS and others — faces uncertainty in this space. Elevance Health offers an appealing valuation and demonstrates strong fundamentals in its commercial business, capital efficiency and shareholder returns. However, ongoing pressures from rising medical costs, government program headwinds, and regulatory uncertainties temper the bullish case. With a Zacks Rank #3 (Hold), the stock reflects a balanced risk-reward profile. It may not be a screaming buy at the moment, but it remains a solid name to watch, especially for long-term investors seeking stability, value and consistent execution in the healthcare space. Patience may be warranted until clearer signals on regulatory outcomes emerge. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
23-05-2025
- Business
- Yahoo
UnitedHealth vs. Elevance: Which Healthcare Stock Has More Upside?
UnitedHealth Group Incorporated UNH and Elevance Health, Inc. ELV are two of the largest healthcare plan providers in the U.S. market. Both operate at a massive scale, with strong reputations, diversified healthcare offerings and solid financial track records. They are also among the most widely held stocks in the healthcare sector, frequently seen as defensive plays in volatile markets. The health maintenance organization space has been under pressure in recent quarters due to rising costs and reimbursement uncertainties. However, the long-term outlook remains promising, especially with the growing demand for managed care services. As investors seek stability and growth, UNH and ELV are natural contenders. Let's dive deep and closely compare the fundamentals of the two stocks to determine which one holds more promise now. UnitedHealth is the industry's juggernaut, with unmatched scale across insurance and health services through its Optum unit. It's a consistent performer, with decades of earnings growth and a history of prudent capital allocation. The company's size offers negotiating leverage and operational efficiency, supporting its ability to weather macroeconomic pressures. However, things are not going smoothly for the company at the moment. Following some major events since early last year, the stock's market cap declined from $566.7 billion on Nov. 8, 2024, to $269.1 billion currently. In its most recent quarter, UnitedHealth missed both the earnings and revenue estimates due to lower-than-expected premiums and elevated medical costs, caused by growing utilization. It also withdrew its 2025 financial guidance. This has raised concerns about near-term earnings volatility. UnitedHealth Group Incorporated price-consensus-eps-surprise-chart | UnitedHealth Group Incorporated Quote The company also announced a significant leadership change: CEO Andrew Witty, who took the role in 2021, is stepping down, with former CEO Stephen Hemsley returning to lead. Adding to the turmoil, the Wall Street Journal reported that UnitedHealth is facing a criminal investigation related to potential Medicare fraud. These developments have only deepened investor concerns and accelerated the stock's decline. Still, UnitedHealth's broad diversification, across commercial insurance, Medicare Advantage, Medicaid, and Optum's data-driven services, gives it a strong buffer against sector-specific risks. It also benefits from consistent free cash flow and a commitment to shareholder returns through dividends and buybacks. Its dividend yield of 2.83% is higher than ELV's 1.78%. Elevance Health may be smaller in size, but it's showing sharper operational momentum. ELV has increasingly streamlined its business mix and has doubled down on execution, particularly in government-backed plans like Medicaid and Medicare Advantage. In its latest quarterly report, the company beat estimates on both top and bottom lines thanks to rising premiums, investment income and product revenues. Additionally, it reaffirmed its full-year outlook, despite growing concerns over rising medical costs in the industry, something UnitedHealth has not done amid similar sector dynamics. Elevance Health, Inc. price-consensus-eps-surprise-chart | Elevance Health, Inc. Quote Its premiums increased 14.5% year over year to $40.9 billion in the first quarter. ELV's operating expense ratio improved 70 bps year over year to 10.9%, which is better than UNH's 12.4% recorded in the March quarter. Elevance witnessed growth in Medicare Advantage and Individual ACA memberships in the quarter. UNH's UnitedHealthcare business, meanwhile, is dependent on self-funded commercial benefits memberships. Elevance's long-term debt to capital of 39.7% is lower than UnitedHealth's 42.7%, indicating less usage of leverage, which typically means lower interest obligations and less vulnerability to a high-interest-rate environment. Zacks Consensus Estimates favor Elevance at this stage. ELV has seen upward revisions in EPS estimates for the current year, while UNH has witnessed multiple downward revisions. The consensus estimate for ELV's 2025 earnings indicates a 4.2% increase from a year ago, while the same for revenues predicts 11.2% growth. On the other hand, the Zacks Consensus Estimate for UNH's 2025 revenues indicates 12.9% year-over-year growth, but the same for EPS signals a 15.5% decline. Valuation also favors ELV. While UNH trades at a forward P/E of 11.76X, ELV trades at a more modest 10.60. This valuation gap gives Elevance a more attractive risk-reward profile. In contrast, UNH's premium pricing could limit near-term upside unless it delivers clear margin improvements. Image Source: Zacks Investment Research Over the year-to-date period, ELV shares have gained 4.2%, outperforming the industry and the S&P 500 Index's decline, supported by stronger earnings momentum and clearer guidance. Meanwhile, UNH faced selloffs tied to medical costs and investigation concerns. Its shares plunged 41.4% during the same time. Image Source: Zacks Investment Research Both UnitedHealth and Elevance Health are blue-chip names with solid track records. UnitedHealth offers scale and diversification, but faces short-term challenges with care costs and margin pressures. Elevance, meanwhile, is showing stronger execution, tighter cost control, and a cleaner growth narrative. With a more attractive valuation, favorable earnings revisions, and better price performance, Elevance Health stands out as the health insurer with more upside right now. The company currently has a Zacks Rank #3 (Hold), while UnitedHealth carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Elevance Health, Inc. (ELV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
